Shots: The US FDA has granted clearance to the QIAstat-Dx BCID GN Plus AMR Panel, completing QIAGEN’s US bloodstream infection testing portfolio with coverage of gram-negative bacteria & antimicrobial resistance markers The new panel can detect 13 gram-negative bacterial targets & 18 AMR markers from positive blood cultures in about one hour, complementing the previously…

Shots: The US FDA has granted clearance to QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infection testing  The panel identifies 20 gram-positive bacterial & fungal pathogen targets & 10 antimicrobial resistance markers, delivering results in ~1 hour to support rapid clinical decision-making & antimicrobial stewardship Clearance supports QIAGEN’s expansion of its US bloodstream infection…